At J&J, Oncology Closes In On Immunology As The Leading Pharma Franchise
Global oncology sales grew 45% to $2.31bn in the first quarter, powered by strong growth of Darzalex, Imbruvica and Zytiga, narrowing the gap with J&J's top-selling immunology franchise.
You may also be interested in...
Janssen global oncology therapeutic area head Peter Lebowitz talked to Scrip about the company's next big ambitions in lung, bladder and prostate cancer.
The pharmaceutical business continues to withstand the arrival of more Remicade biosimilars and the firm maintains it will have solid growth even with generic competition to its Zytiga.
Recent launches Tremfya and Erleada are viewed as catalysts for continuing growth, along with ambitious plans to add indications for Imbruvica, Darzalex and Stelara.